

Paolo Marchetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/81784/publications.pdf>

Version: 2024-02-01

367
papers

11,054
citations

46918

47
h-index

60497

81
g-index

381
all docs

381
docs citations

381
times ranked

15992
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 521-536. | 5.1 | 486 |
| 2 | Endocrine Side Effects Induced by Immune Checkpoint Inhibitors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1361-1375. | 1.8 | 358 |
| 3 | Antibodyâ€“Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Nonâ€“small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. <i>Clinical Cancer Research</i> , 2019, 25, 989-999. | 3.2 | 315 |
| 4 | A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. , 2019, 7, 57. | | 275 |
| 5 | Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study. <i>Oncotarget</i> , 2017, 8, 79884-79896. | 0.8 | 239 |
| 6 | Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 675-683. | 2.0 | 230 |
| 7 | Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer. <i>Human Mutation</i> , 2001, 18, 163-164. | 1.1 | 215 |
| 8 | Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 510-520. | 5.1 | 183 |
| 9 | Use of strong opioids in advanced cancer pain: a randomized trial. <i>Journal of Pain and Symptom Management</i> , 2004, 27, 409-416. | 0.6 | 160 |
| 10 | Clinical experience with ipilimumab 3Âµg/kg: real-world efficacy and safety data from an expanded access programme cohort. <i>Journal of Translational Medicine</i> , 2014, 12, 116. | 1.8 | 149 |
| 11 | Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. <i>European Journal of Cancer</i> , 2014, 50, 121-127. | 1.3 | 149 |
| 12 | Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. <i>Clinical Cancer Research</i> , 2019, 25, 3839-3846. | 3.2 | 147 |
| 13 | Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. <i>Oncologist</i> , 2019, 24, e327-e337. | 1.9 | 131 |
| 14 | Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. <i>Journal of Immunology Research</i> , 2020, 2020, 1-12. | 0.9 | 127 |
| 15 | Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. <i>Clinical Lung Cancer</i> , 2019, 20, 237-247.e1. | 1.1 | 118 |
| 16 | Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment. <i>Journal of Translational Medicine</i> , 2020, 18, 49. | 1.8 | 114 |
| 17 | Immunization of Stage IV Melanoma Patients with Melan-A/MART-1 and gp100 Peptides plus IFN-Î± Results in the Activation of Specific CD8+ T Cells and Monocyte/Dendritic Cell Precursors. <i>Cancer Research</i> , 2006, 66, 4943-4951. | 0.4 | 108 |
| 18 | Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. <i>Journal of Neuro-Oncology</i> , 2014, 118, 109-116. | 1.4 | 103 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. <i>European Journal of Endocrinology</i> , 2013, 169, R153-R164. | 1.9 | 102 |
| 20 | Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 1092-1098. | 0.4 | 98 |
| 21 | First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. <i>European Journal of Cancer</i> , 2020, 130, 155-167. | 1.3 | 98 |
| 22 | Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 30. | 3.5 | 97 |
| 23 | Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?. <i>Journal of Translational Medicine</i> , 2018, 16, 219. | 1.8 | 96 |
| 24 | Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program. <i>Cancer Investigation</i> , 2014, 32, 144-149. | 0.6 | 90 |
| 25 | Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. <i>European Journal of Cancer</i> , 2020, 128, 17-26. | 1.3 | 85 |
| 26 | Triple positive breast cancer: A distinct subtype?. <i>Cancer Treatment Reviews</i> , 2015, 41, 69-76. | 3.4 | 83 |
| 27 | Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. <i>European Journal of Cancer</i> , 2018, 100, 126-134. | 1.3 | 83 |
| 28 | Metronomic chemotherapy for cancer treatment: a decade of clinical studies. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 13-33. | 1.1 | 81 |
| 29 | Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. <i>European Journal of Cancer</i> , 2021, 142, 18-28. | 1.3 | 81 |
| 30 | Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. , 2021, 9, e002421. | | 80 |
| 31 | Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1146-1155. | 0.5 | 77 |
| 32 | The sexist behaviour of immune checkpoint inhibitors in cancer therapy?. <i>Oncotarget</i> , 2017, 8, 99336-99346. | 0.8 | 76 |
| 33 | Network Analysis of Gut Microbiome and Metabolome to Discover Microbiota-Linked Biomarkers in Patients Affected by Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8730. | 1.8 | 75 |
| 34 | Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 552. | 2.2 | 74 |
| 35 | Weekly administration of paclitaxel: theoretical and clinical basis. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 44, 3-13. | 2.0 | 70 |
| 36 | Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 27-42. | 2.0 | 68 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents. <i>European Journal of Pharmacology</i> , 2019, 862, 172621. | 1.7 | 65 |
| 38 | Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. <i>Journal of Clinical Medicine</i> , 2018, 7, 542. | 1.0 | 64 |
| 39 | Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 97-107. | 2.0 | 61 |
| 40 | Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study.. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166042. | 1.8 | 61 |
| 41 | Early onset pancreatic cancer: Risk factors, presentation and outcome. <i>Pancreatology</i> , 2015, 15, 151-155. | 0.5 | 60 |
| 42 | Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2209-2221. | 2.0 | 60 |
| 43 | A Systematic Review of Experimental and Clinical Acupuncture in Chemotherapy-Induced Peripheral Neuropathy. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-7. | 0.5 | 59 |
| 44 | FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1478-1485. | 0.8 | 59 |
| 45 | Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. <i>European Journal of Human Genetics</i> , 2004, 12, 899-906. | 1.4 | 55 |
| 46 | Global mapping of cancers: The Cancer Genome Atlas and beyond. <i>Molecular Oncology</i> , 2021, 15, 2823-2840. | 2.1 | 55 |
| 47 | Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. <i>United European Gastroenterology Journal</i> , 2018, 6, 1039-1048. | 1.6 | 54 |
| 48 | Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study. <i>Journal of Cancer</i> , 2014, 5, 320-327. | 1.2 | 53 |
| 49 | Italian Oncological Pain Survey (IOPS). <i>Clinical Journal of Pain</i> , 2015, 31, 214-221. | 0.8 | 53 |
| 50 | A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. <i>Oncotarget</i> , 2017, 8, 56921-56931. | 0.8 | 53 |
| 51 | A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab. <i>Journal of Translational Medicine</i> , 2019, 17, 99. | 1.8 | 52 |
| 52 | Dermscopic patterns of cutaneous melanoma metastases. <i>Melanoma Research</i> , 2004, 14, 367-373. | 0.6 | 51 |
| 53 | Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 67-72. | 2.0 | 51 |
| 54 | Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 498-508.e2. | 1.1 | 50 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?. BioMed Research International, 2017, 2017, 1-7. | 0.9 | 49 |
| 56 | Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study. Oncotarget, 2018, 9, 30268-30278. | 0.8 | 49 |
| 57 | Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. Oncotarget, 2017, 8, 8890-8899. | 0.8 | 48 |
| 58 | TK Inhibitor Pazopanib Primes DCs by Downregulation of the β -Catenin Pathway. Cancer Immunology Research, 2018, 6, 711-722. | 1.6 | 47 |
| 59 | Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis. Frontiers in Immunology, 2021, 12, 705096. | 2.2 | 47 |
| 60 | The Exponential Phase of the Covid-19 Pandemic in Central Italy: An Integrated Care Pathway. International Journal of Environmental Research and Public Health, 2020, 17, 3792. | 1.2 | 46 |
| 61 | Brain Metastases: Surgical Treatment and Overall Survival. World Neurosurgery, 2017, 97, 169-177. | 0.7 | 45 |
| 62 | Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. European Journal of Cancer, 2020, 134, 19-28. | 1.3 | 45 |
| 63 | Factors Influencing the Clinical Presentation of Breakthrough Pain in Cancer Patients. Cancers, 2018, 10, 175. | 1.7 | 44 |
| 64 | Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. Lung Cancer, 2019, 137, 38-42. | 0.9 | 44 |
| 65 | Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncology, 2014, 10, 975-983. | 1.1 | 43 |
| 66 | Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab. Translational Lung Cancer Research, 2020, 9, 1533-1542. | 1.3 | 43 |
| 67 | Cytokines, Fatigue, and Cutaneous Erythema in Early Stage Breast Cancer Patients Receiving Adjuvant Radiation Therapy. BioMed Research International, 2014, 2014, 1-7. | 0.9 | 42 |
| 68 | Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic) Tj ETQq0 0 0 rgBT /Overlock 10 T | 1.0 | 42 |
| 69 | Nutritional support for cancer patients: still a neglected right?. Supportive Care in Cancer, 2017, 25, 3001-3004. | 1.0 | 42 |
| 70 | KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.. Journal of Clinical Oncology, 2019, 37, 9013-9013. | 0.8 | 42 |
| 71 | Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines. Oncotarget, 2018, 9, 25714-25722. | 0.8 | 42 |
| 72 | "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (Flr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer, 2010, 10, 567. | 1.1 | 41 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1607. | 1.8 | 40 |
| 74 | Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. <i>The RETROHER study. Breast Cancer Research and Treatment</i> , 2014, 147, 599-607. | 1.1 | 39 |
| 75 | Circulating Tumor Cells Count Predicts Survival in Colorectal Cancer Patients. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 23, 279-284. | 0.5 | 39 |
| 76 | Awareness of cancer, satisfaction with care, emotional distress, and adjustment to illness: an Italian multicenter study. <i>Psycho-Oncology</i> , 2015, 24, 1088-1096. | 1.0 | 38 |
| 77 | Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017, 82, 237-246. | 1.3 | 38 |
| 78 | Dignity and Psychosocial-Related Variables in Advanced and Nonadvanced Cancer Patients by Using the Patient Dignity Inventory-Italian Version. <i>Journal of Pain and Symptom Management</i> , 2017, 53, 279-287. | 0.6 | 38 |
| 79 | The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. <i>Vaccines</i> , 2020, 8, 203. | 2.1 | 38 |
| 80 | Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 139. | 1.8 | 36 |
| 81 | The Palliative-Supportive Care Unit in a Comprehensive Cancer Center as Crossroad for Patients's Oncological Pathway. <i>PLoS ONE</i> , 2016, 11, e0157300. | 1.1 | 36 |
| 82 | High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: A case series and the state of art. <i>Digestive and Liver Disease</i> , 2016, 48, 1503-1505. | 0.4 | 35 |
| 83 | CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives. <i>Cancers</i> , 2021, 13, 332. | 1.7 | 35 |
| 84 | Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 4737-4745. | 3.2 | 35 |
| 85 | Overcoming Cultural Barriers to Giving Bad News: Feasibility of Training to Promote Truth-Telling to Cancer Patients. <i>Journal of Cancer Education</i> , 2009, 24, 180-185. | 0.6 | 34 |
| 86 | Treatment-related side effects and quality of life in cancer patients. <i>Supportive Care in Cancer</i> , 2012, 20, 2553-2557. | 1.0 | 34 |
| 87 | Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness. <i>International Journal of Oncology</i> , 2016, 48, 1581-1589. | 1.4 | 34 |
| 88 | Precision medicine in breast cancer: From clinical trials to clinical practice. <i>Cancer Treatment Reviews</i> , 2021, 98, 102223. | 3.4 | 34 |
| 89 | Is a Preoperative Assessment of the Early Recurrence of Pancreatic Cancer Possible after Complete Surgical Resection?. <i>Gut and Liver</i> , 2014, 8, 102-108. | 1.4 | 34 |
| 90 | Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. <i>PLoS ONE</i> , 2014, 9, e105268. | 1.1 | 33 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | High prevalence of ALK+/ROS1+ cases in pulmonary adenocarcinoma of adolescents and young adults. <i>Lung Cancer</i> , 2016, 97, 95-98. | 0.9 | 33 |
| 92 | Epidemiology and Characteristics of Episodic Breathlessness in Advanced Cancer Patients: An Observational Study. <i>Journal of Pain and Symptom Management</i> , 2016, 51, 17-24. | 0.6 | 33 |
| 93 | Current challenges in HER2-positive breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 211-221. | 2.0 | 33 |
| 94 | Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting. <i>Journal of Cellular Physiology</i> , 2018, 233, 2313-2323. | 2.0 | 33 |
| 95 | Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases. <i>Anticancer Research</i> , 2019, 39, 4265-4271. | 0.5 | 33 |
| 96 | Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. <i>Lung Cancer</i> , 2020, 140, 59-64. | 0.9 | 33 |
| 97 | “Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome. <i>Oncotarget</i> , 2016, 7, 17932-17944. | 0.8 | 33 |
| 98 | Intradermal lymphoscintigraphy at rest and after exercise: a new technique for the functional assessment of the lymphatic system in patients with lymphoedema. <i>Nuclear Medicine Communications</i> , 2010, 31, 547-551. | 0.5 | 32 |
| 99 | Premetastatic niche: ready for new therapeutic interventions?. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S119-S129. | 1.5 | 32 |
| 100 | Being positive despite illness: The contribution of positivity to the quality of life of cancer patients. <i>Psychology and Health</i> , 2016, 31, 524-534. | 1.2 | 32 |
| 101 | The factor structure and use of the Demoralization Scale (DS&T) in Italian cancer patients. <i>Psycho-Oncology</i> , 2017, 26, 1965-1971. | 1.0 | 32 |
| 102 | Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 279. | 3.5 | 32 |
| 103 | Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 547. | 3.4 | 32 |
| 104 | A Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of 5-Fluorouracil Degradation Rate by Intact Peripheral Blood Mononuclear Cells. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 482-488. | 1.0 | 31 |
| 105 | The Supportive Care Task Force at the University of L'Aquila: 2-years experience. <i>Supportive Care in Cancer</i> , 2005, 13, 351-355. | 1.0 | 30 |
| 106 | Arterial thrombotic events and acute coronary syndromes with cancer drugs: Are growth factors the missed link?. <i>International Journal of Cardiology</i> , 2013, 167, 2421-2429. | 0.8 | 30 |
| 107 | A multicenter REtrospective observational study of first-line treatment with PERTuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. <i>Cancer Biology and Therapy</i> , 2019, 20, 192-200. | 1.5 | 30 |
| 108 | Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3528. | 1.8 | 30 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1. <i>Frontiers in Immunology</i> , 2020, 11, 1243. | 2.2 | 30 |
| 110 | Effectiveness of Liver Metastasectomies in Patients With Metastatic Colorectal Cancer Treated With Flr-B/FOx Triplet Chemotherapy Plus Bevacizumab. <i>Clinical Colorectal Cancer</i> , 2012, 11, 119-126. | 1.0 | 29 |
| 111 | Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors. <i>Pancreas</i> , 2018, 47, 759-771. | 0.5 | 29 |
| 112 | Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival. <i>Medical Oncology</i> , 2018, 35, 111. | 1.2 | 29 |
| 113 | Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center. <i>Journal of Clinical Medicine</i> , 2019, 8, 910. | 1.0 | 28 |
| 114 | The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 651. | 1.1 | 28 |
| 115 | KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2065-2077. | 0.5 | 28 |
| 116 | Efficacy of Treatment With Tetracyclines to Prevent Acneiform Eruption Secondary to Cetuximab Therapy. <i>Archives of Dermatology</i> , 2005, 141, 1173-4. | 1.7 | 27 |
| 117 | Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 289-296. | 1.1 | 27 |
| 118 | Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. <i>Frontiers in Immunology</i> , 2017, 8, 386. | 2.2 | 27 |
| 119 | New paradigm for stage III melanoma: from surgery to adjuvant treatment. <i>Journal of Translational Medicine</i> , 2019, 17, 266. | 1.8 | 27 |
| 120 | Position Paper of the Italian Association of Medical Oncology on Early Palliative Care in Oncology Practice (Simultaneous Care). <i>Tumori</i> , 2017, 103, 9-14. | 0.6 | 26 |
| 121 | Tobacco, Alcohol and Family History of Cancer as Risk Factors of Oral Squamous Cell Carcinoma: Case-Control Retrospective Study. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 3896. | 1.3 | 26 |
| 122 | The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103567. | 2.0 | 26 |
| 123 | Predictors of existential and religious well-being among cancer patients. <i>Supportive Care in Cancer</i> , 2011, 19, 1931-1937. | 1.0 | 25 |
| 124 | Use of interim [¹⁸ F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy. <i>Leukemia and Lymphoma</i> , 2012, 53, 263-269. | 0.6 | 25 |
| 125 | Continuous, low-dose capecitabine for patients with recurrent colorectal cancer. <i>Medical Oncology</i> , 2015, 32, 54. | 1.2 | 25 |
| 126 | Current achievements and future perspectives of metronomic chemotherapy. <i>Investigational New Drugs</i> , 2017, 35, 359-374. | 1.2 | 25 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. <i>European Journal of Cancer</i> , 2017, 83, 106-115. | 1.3 | 25 |
| 128 | CT based radiomic approach on first line pembrolizumab in lung cancer. <i>Scientific Reports</i> , 2021, 11, 6633. | 1.6 | 25 |
| 129 | Changes of Topoisomerase III \pm Expression in Breast Tumors after Neoadjuvant Chemotherapy Predicts Relapse-Free Survival. <i>Clinical Cancer Research</i> , 2006, 12, 1501-1506. | 3.2 | 24 |
| 130 | Short-term Radiotherapy followed by Adjuvant Chemotherapy in Poor-Prognosis Patients with Glioblastoma. <i>Tumori</i> , 2010, 96, 60-64. | 0.6 | 24 |
| 131 | Chemotherapy for the Biliary Tract Cancers: Moving Toward Improved Survival Time. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 396-404. | 0.6 | 24 |
| 132 | Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 826-831. | 1.5 | 24 |
| 133 | Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2. <i>Frontiers in Chemistry</i> , 2020, 8, 590263. | 1.8 | 24 |
| 134 | The role of opioids in cancer response to immunotherapy. <i>Journal of Translational Medicine</i> , 2021, 19, 119. | 1.8 | 24 |
| 135 | Predictors of mood disorders in cancer patients's caregivers. <i>Supportive Care in Cancer</i> , 2013, 21, 643-647. | 1.0 | 23 |
| 136 | An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. <i>ClinicoEconomics and Outcomes Research</i> , 2013, 5, 125. | 0.7 | 23 |
| 137 | Association Between Proton Pump Inhibitors and Metronomic Capecitabine as Salvage Treatment for Patients With Advanced Gastrointestinal Tumors: A Randomized Phase II Trial. <i>Clinical Colorectal Cancer</i> , 2016, 15, 377-380. | 1.0 | 23 |
| 138 | SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab. <i>Medical Oncology</i> , 2017, 34, 75. | 1.2 | 23 |
| 139 | Study of histopathologic parameters to define the prognosis of stage II colon cancer. <i>International Journal of Colorectal Disease</i> , 2019, 34, 905-913. | 1.0 | 23 |
| 140 | Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. <i>Oncologist</i> , 2019, 24, 385-393. | 1.9 | 23 |
| 141 | Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients. <i>Journal of Personalized Medicine</i> , 2020, 10, 208. | 1.1 | 23 |
| 142 | Changes of microbiome profile during nivolumab treatment in NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15020-e15020. | 0.8 | 23 |
| 143 | Different Expressivity of BRCA1 and BRCA2: Analysis of 179 Italian Pedigrees with Identified Mutation. <i>Breast Cancer Research and Treatment</i> , 2003, 81, 71-79. | 1.1 | 22 |
| 144 | High Expression of the Mismatch Repair Protein MSH6 Is Associated With Poor Patient Survival in Melanoma. <i>American Journal of Clinical Pathology</i> , 2014, 142, 121-132. | 0.4 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical Practice. <i>Analytical Cellular Pathology</i> , 2018, 2018, 1-12. | 0.7 | 22 |
| 146 | CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2018, 97, 59-61. | 1.3 | 22 |
| 147 | Steroid receptor enhancement by natural interferon- β in advanced breast cancer. <i>European Journal of Cancer</i> , 1993, 29, 329-333. | 1.3 | 21 |
| 148 | Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 83-91. | 1.1 | 21 |
| 149 | Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort. <i>Oncotarget</i> , 2016, 7, 20612-20620. | 0.8 | 21 |
| 150 | Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients. <i>Future Oncology</i> , 2016, 12, 2071-2075. | 1.1 | 21 |
| 151 | Ion Channel Expression in Human Melanoma Samples: In Silico Identification and Experimental Validation of Molecular Targets. <i>Cancers</i> , 2019, 11, 446. | 1.7 | 21 |
| 152 | Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience. <i>Journal of Cellular Physiology</i> , 2019, 234, 7708-7717. | 2.0 | 21 |
| 153 | Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2620. | 1.7 | 21 |
| 154 | Glucocorticoid Receptors Predict Response to Combination Chemotherapy in Patients with Acute Lymphoblastic Leukemia. <i>Oncology</i> , 1987, 44, 13-16. | 0.9 | 20 |
| 155 | Clinical Impact of Highly Purified, Whey Proteins in Patients Affected With Colorectal Cancer Undergoing Chemotherapy: Preliminary Results of a Placebo-Controlled Study. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541986692. | 0.8 | 20 |
| 156 | Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice. <i>Journal of Translational Medicine</i> , 2019, 17, 376. | 1.8 | 20 |
| 157 | Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898. | 1.7 | 20 |
| 158 | Information Needs of Patients With Melanoma. <i>Clinical Journal of Oncology Nursing</i> , 2012, 16, 625-632. | 0.3 | 19 |
| 159 | Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS). <i>Advances in Therapy</i> , 2017, 34, 120-135. | 1.3 | 19 |
| 160 | CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 569-576. | 1.4 | 19 |
| 161 | Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter SLAVE- Study. <i>Cancers</i> , 2020, 12, 1259. | 1.7 | 19 |
| 162 | Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. <i>Journal of Cellular Physiology</i> , 2020, 235, 7900-7910. | 2.0 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098765. | 1.4 | 19 |
| 164 | Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e457-e470. | 1.0 | 18 |
| 165 | Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC. <i>Anticancer Research</i> , 2018, 38, 6029-6039. | 0.5 | 18 |
| 166 | Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?. <i>Clinical Endocrinology</i> , 2020, 92, 258-265. | 1.2 | 18 |
| 167 | Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice. <i>Frontiers in Oncology</i> , 2021, 11, 657639. | 1.3 | 18 |
| 168 | Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective Study. <i>Cancers</i> , 2021, 13, 6355. | 1.7 | 18 |
| 169 | Exploring the Prognostic Role of Microsatellite Instability in Patients With Stage II Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Clinical Colorectal Cancer</i> , 2017, 16, e55-e59. | 1.0 | 17 |
| 170 | GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 1396-1401. | 2.0 | 17 |
| 171 | Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer. <i>Clinical Drug Investigation</i> , 2019, 39, 825-834. | 1.1 | 17 |
| 172 | Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPSAEMS study. <i>European Journal of Pain</i> , 2019, 23, 719-726. | 1.4 | 17 |
| 173 | Glucocorticoid receptor studies in human leukemia. <i>The Journal of Steroid Biochemistry</i> , 1981, 15, 261-268. | 1.3 | 16 |
| 174 | Postoperative adjuvant chemoradiation in completely resected locally advanced gastric cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 1069-1075. | 0.4 | 16 |
| 175 | Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software. <i>European Journal of Human Genetics</i> , 2006, 14, 49-54. | 1.4 | 16 |
| 176 | Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not). <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 489-490. | 1.1 | 16 |
| 177 | Differential Denaturation of Serum Proteome Reveals a Significant Amount of Hidden Information in Complex Mixtures of Proteins. <i>PLoS ONE</i> , 2013, 8, e57104. | 1.1 | 16 |
| 178 | A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer. <i>Anti-Cancer Drugs</i> , 2016, 27, 106-111. | 0.7 | 16 |
| 179 | Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 450-459. | 1.4 | 16 |
| 180 | Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. <i>Scientific Reports</i> , 2017, 7, 10597. | 1.6 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer. <i>Journal of Cellular Physiology</i> , 2017, 232, 1571-1578. | 2.0 | 16 |
| 182 | Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting. <i>Journal of Translational Medicine</i> , 2018, 16, 129. | 1.8 | 16 |
| 183 | Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience. <i>Radiation Oncology</i> , 2019, 14, 205. | 1.2 | 16 |
| 184 | Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios. <i>Journal of Cancer</i> , 2019, 10, 5903-5914. | 1.2 | 16 |
| 185 | Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 1525. | 1.0 | 16 |
| 186 | High sensitivity of detection of TP53 somatic mutations by fluorescence-assisted mismatch analysis. <i>Genes Chromosomes and Cancer</i> , 2002, 35, 86-91. | 1.5 | 15 |
| 187 | New mutations and protein variants of NBS1 are identified in cancer cell lines. <i>Genes Chromosomes and Cancer</i> , 2003, 36, 198-204. | 1.5 | 15 |
| 188 | Topical Morphine in the Treatment of Painful Ulcers. <i>Journal of Pain and Symptom Management</i> , 2005, 30, 304-305. | 0.6 | 15 |
| 189 | Clinical Classification of <i>BRCA1</i> DNA Missense Variants: H1686Q Is a Novel Pathogenic Mutation Occurring in the Ontogenetically Invariant THV Motif of the N-Terminal BRCT Domain. <i>Journal of Clinical Oncology</i> , 2008, 26, 4212-4214. | 0.8 | 15 |
| 190 | Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram. <i>Oncologist</i> , 2015, 20, 1111-1118. | 1.9 | 15 |
| 191 | Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 57-68. | 2.0 | 15 |
| 192 | Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma. <i>Medicine (United States)</i> , 2010, 89, 1015-1016. | 0.4 | 15 |
| 193 | Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report. <i>Drug Safety - Case Reports</i> , 2018, 5, 12. | 0.9 | 15 |
| 194 | A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. <i>Cancers</i> , 2019, 11, 147. | 1.7 | 15 |
| 195 | No Evidence of SARS-CoV-2 Circulation in Rome (Italy) during the Pre-Pandemic Period: Results of a Retrospective Surveillance. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8461. | 1.2 | 15 |
| 196 | Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. <i>Tumori</i> , 2011, 97, 690-2. | 0.6 | 15 |
| 197 | Targeting the <i>PTTG1</i> oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib. <i>Oncotarget</i> , 2017, 8, 113472-113493. | 0.8 | 15 |
| 198 | Resistance to abiraterone in castration-resistant prostate cancer: a review of the literature. <i>Anticancer Research</i> , 2014, 34, 6265-9. | 0.5 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Adjuvant endocrine therapy for perimenopausal women with early breast cancer. <i>Breast</i> , 2009, 18, 2-7. | 0.9 | 14 |
| 200 | The role of stereotactic body radiation therapy in oligometastatic colorectal cancer. <i>Medicine (United States)</i> , 2017, 96, e9023. | 0.4 | 14 |
| 201 | Statins and immunotherapy: Togetherness makes strength The potential effect of statins on immunotherapy for <sc>NSCLC</sc>. <i>Cancer Reports</i> , 2021, 4, e1368. | 0.6 | 14 |
| 202 | Molecular tests and target therapies in oncology: recommendations from the Italian workshop. <i>Future Oncology</i> , 2021, 17, 3529-3539. | 1.1 | 14 |
| 203 | Pharmacogenomics in lung cancer chemotherapy: a review of what the oncologist should know. <i>Anticancer Research</i> , 2014, 34, 5241-50. | 0.5 | 14 |
| 204 | Genomic and epigenomic alterations in prostate cancer. <i>Frontiers in Endocrinology</i> , 2012, 3, 128. | 1.5 | 13 |
| 205 | Metformin and breast cancer: Basic knowledge in clinical context. <i>Cancer Treatment Reviews</i> , 2015, 41, 441-447. | 3.4 | 13 |
| 206 | Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. <i>Journal of Translational Medicine</i> , 2019, 17, 296. | 1.8 | 13 |
| 207 | Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes. , 2020, 8, e000946. | | 13 |
| 208 | The 5-Ws of immunotherapy in head and neck cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103041. | 2.0 | 13 |
| 209 | Patient perception of disease control and psychological distress. <i>Cancer Management and Research</i> , 2012, 4, 335. | 0.9 | 12 |
| 210 | Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial. <i>Journal of Cellular Physiology</i> , 2016, 231, 2541-2547. | 2.0 | 12 |
| 211 | Bevacizumab as First-Line Treatment in HER2-Negative Advanced Breast Cancer: Pros and Cons. <i>Tumori</i> , 2016, 102, 472-480. | 0.6 | 12 |
| 212 | Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients. <i>Pharmacogenomics</i> , 2017, 18, 821-830. | 0.6 | 12 |
| 213 | Patient database analysis of fulvestrant 500mg in the treatment of metastatic breast cancer: A European perspective. <i>Breast</i> , 2017, 32, 247-255. | 0.9 | 12 |
| 214 | Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 157-164. | 0.8 | 12 |
| 215 | Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. <i>Cancer Biology and Therapy</i> , 2018, 19, 328-334. | 1.5 | 12 |
| 216 | Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study. <i>Supportive Care in Cancer</i> , 2018, 26, 4021-4029. | 1.0 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | Impact of tumor site on the prognosis of small bowel adenocarcinoma. <i>Tumori</i> , 2019, 105, 524-528. | 0.6 | 12 |
| 218 | Opioid-induced bowel dysfunction: suggestions from a multidisciplinary expert Board. <i>Supportive Care in Cancer</i> , 2019, 27, 4083-4090. | 1.0 | 12 |
| 219 | Primary squamous cell carcinoma of major salivary gland: Sapienza Head and Neck Unit's clinical recommendations. <i>Rare Tumors</i> , 2020, 12, 203636132097352. | 0.3 | 12 |
| 220 | Multidimensional Statistical Technique for Interpreting the Spontaneous Breakthrough Cancer Pain Phenomenon. A Secondary Analysis from the IOPS-MS Study. <i>Cancers</i> , 2021, 13, 4018. | 1.7 | 12 |
| 221 | Gabapentin in the treatment of severe sweating experienced by advanced cancer patients. <i>Supportive Care in Cancer</i> , 2006, 14, 389-391. | 1.0 | 11 |
| 222 | Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1183-1198. | 1.1 | 11 |
| 223 | The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer. <i>Anti-Cancer Drugs</i> , 2016, 27, 1044-1049. | 0.7 | 11 |
| 224 | Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103176. | 2.0 | 11 |
| 225 | H-Ras gene takes part to the host immune response to COVID-19. <i>Cell Death Discovery</i> , 2021, 7, 158. | 2.0 | 11 |
| 226 | Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 33381-33390. | 0.8 | 11 |
| 227 | Interventions to Reduce Neurological Symptoms in Patients with GBM Receiving Radiotherapy: From Theory to Clinical Practice. <i>Anticancer Research</i> , 2018, 38, 2423-2427. | 0.5 | 11 |
| 228 | Prediction of clinical response to glucocorticoids in children with acute lymphoblastic leukemia. <i>European Paediatric Haematology and Oncology</i> , 1984, 1, 33-36. | 0.3 | 10 |
| 229 | Complete Regression of a Non-small Cell Lung Cancer Choroidal Metastasis with Intravitreal Bevacizumab. <i>Journal of Thoracic Oncology</i> , 2012, 7, 468-469. | 0.5 | 10 |
| 230 | Gastric Metastases From Testicular Cancer: Case Report and Review of Literature. <i>Journal of Gastrointestinal Cancer</i> , 2014, 45, 22-24. | 0.6 | 10 |
| 231 | Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?. <i>PLoS ONE</i> , 2016, 11, e0163105. | 1.1 | 10 |
| 232 | 5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX. <i>Anti-Cancer Drugs</i> , 2017, 28, 322-326. | 0.7 | 10 |
| 233 | A nomogram to predict 5-fluorouracil toxicity. <i>Anti-Cancer Drugs</i> , 2017, 28, 551-556. | 0.7 | 10 |
| 234 | Resolution of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) during Nivolumab therapy for non-small cell lung cancer: a case report.. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, e17-e20. | 1.6 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137+T-cells. <i>EBioMedicine</i> , 2020, 62, 103098. | 2.7 | 10 |
| 236 | Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 2648. | 1.7 | 10 |
| 237 | Breakthrough Cancer Pain Clinical Features and Differential Opioids Response: A Machine Learning Approach in Patients With Cancer From the IOPS-MS Study. <i>JCO Precision Oncology</i> , 2020, 4, 1339-1349. | 1.5 | 10 |
| 238 | The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial. <i>Vaccines</i> , 2020, 8, 191. | 2.1 | 10 |
| 239 | New immunological potential markers for triple negative breast cancer: IL18R1, CD53, TRIM, Jaw1, LTB, PTPRCAP. <i>Discover Oncology</i> , 2021, 12, 6. | 0.8 | 10 |
| 240 | Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 1080. | 1.7 | 10 |
| 241 | Effect of MTHFR Polymorphisms on Gastrointestinal Cancer Risk in Italy. <i>World Journal of Oncology</i> , 2015, 6, 394-397. | 0.6 | 10 |
| 242 | Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1027-1037. | 3.2 | 10 |
| 243 | Combined effects of estradiol, leuprorelin, tamoxifen and medroxyprogesterone acetate on cell growth and steroid hormone receptors in breast cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 1994, 120, 605-609. | 1.2 | 9 |
| 244 | A Synchronous Pancreatic Metastasis from Renal Clear Cell Carcinoma, with Unusual CT Characteristics, Completely Regressed after Therapy with Sunitinib. <i>Case Reports in Medicine</i> , 2014, 2014, 1-6. | 0.3 | 9 |
| 245 | Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: a single-center experience and review of the literature. <i>Translational Lung Cancer Research</i> , 2016, 5, 712-719. | 1.3 | 9 |
| 246 | The use of fentanyl in pain management in head and neck cancer patients: a narrative review. <i>British Journal of Pain</i> , 2018, 12, 155-162. | 0.7 | 9 |
| 247 | Treatment responses to antiangiogenetic therapy and chemotherapy in nonsecreting paraganglioma (PGL4) of urinary bladder with SDHB mutation. <i>Medicine (United States)</i> , 2018, 97, e10904. | 0.4 | 9 |
| 248 | Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2365-2373. | 1.2 | 9 |
| 249 | What cancer patients actually know regarding medical cannabis? A cross-sectional survey with a critical analysis of the current attitudes. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1439-1444. | 0.5 | 9 |
| 250 | Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. <i>Oncolmmunology</i> , 2020, 9, 1710389. | 2.1 | 9 |
| 251 | Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2020, 9, LMT26. | 1.5 | 9 |
| 252 | Drugâ€™Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PINÁ® System Comprehensive Approach. <i>Pharmaceuticals</i> , 2021, 14, 67. | 1.7 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study. <i>Tumori</i> , 2022, 108, 250-257. | 0.6 | 9 |
| 254 | Radiotherapy with or without Androgen Deprivation in the Treatment of Localized Adenocarcinoma of the Prostate. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998, 21, 1-5. | 0.6 | 9 |
| 255 | H2020 and Beyond: Skip Discrepancy between Theory and Practice of Personalized Medicine. A Position Paper by the Italian Society of Personalized Medicine. <i>Current Pharmaceutical Biotechnology</i> , 2016, 17, 926-929. | 0.9 | 9 |
| 256 | CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy. <i>Eurasian Journal of Medicine</i> , 2016, 48, 10-14. | 0.2 | 9 |
| 257 | Assessment and treatment of symptoms among Italian medical oncologists. <i>Supportive Care in Cancer</i> , 2005, 13, 865-869. | 1.0 | 8 |
| 258 | Tackling pancreatic cancer with metronomic chemotherapy. <i>Cancer Letters</i> , 2017, 394, 88-95. | 3.2 | 8 |
| 259 | Unexpected serious aplastic anemia from PD-1 inhibitors: beyond what we know. <i>Tumori</i> , 2019, 105, NP48-NP51. | 0.6 | 8 |
| 260 | 5-Fluorouracil degradation rate as a predictive biomarker of toxicity in breast cancer patients treated with capecitabine. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1836-1842. | 0.5 | 8 |
| 261 | Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy. <i>Cancers</i> , 2020, 12, 781. | 1.7 | 8 |
| 262 | The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. <i>Scientific Reports</i> , 2021, 11, 13770. | 1.6 | 8 |
| 263 | Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis. <i>Oncologist</i> , 2020, 25, e928-e935. | 1.9 | 8 |
| 264 | Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. <i>OncoTargets and Therapy</i> , 2013, 6, 1761. | 1.0 | 7 |
| 265 | Positive impact of elastography in breast cancer diagnosis: an institutional experience. <i>Journal of Ultrasound</i> , 2015, 18, 321-327. | 0.7 | 7 |
| 266 | Attitudes Among Patients With Advanced Cancer Toward Euthanasia and Living Wills. <i>Journal of Pain and Symptom Management</i> , 2016, 51, e3-e6. | 0.6 | 7 |
| 267 | The Italian Rare Pancreatic Exocrine Cancer Initiative. <i>Tumori</i> , 2019, 105, 353-358. | 0.6 | 7 |
| 268 | The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1513-1527. | 1.0 | 7 |
| 269 | Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey. <i>Supportive Care in Cancer</i> , 2021, 29, 7845-7854. | 1.0 | 7 |
| 270 | Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes. <i>Anticancer Research</i> , 2017, 37, 2633-2639. | 0.5 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | Presence and steroid inducibility of glutamine synthetase in human leukemic cells. <i>The Journal of Steroid Biochemistry</i> , 1983, 19, 1665-1670. | 1.3 | 6 |
| 272 | Natural Interferon- β Treatment and Steroid Hormone Receptors in Primary Endometrial Cancer. <i>Gynecologic Oncology</i> , 1993, 50, 185-190. | 0.6 | 6 |
| 273 | Knowledge and attitudes of Italian medical oncology residents toward the approach and treatment of pain. <i>Journal of Pain and Symptom Management</i> , 2003, 26, 590-592. | 0.6 | 6 |
| 274 | Pruritus in a patient with advanced cancer successfully treated with continuous infusion of granisetron. <i>Supportive Care in Cancer</i> , 2004, 12, 208-209. | 1.0 | 6 |
| 275 | Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study. <i>BMC Cancer</i> , 2012, 12, 216. | 1.1 | 6 |
| 276 | A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer. <i>Future Oncology</i> , 2016, 12, 2589-2602. | 1.1 | 6 |
| 277 | Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate. <i>Anti-Cancer Drugs</i> , 2017, 28, 110-115. | 0.7 | 6 |
| 278 | Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer. <i>Oncotarget</i> , 2017, 8, 14050-14057. | 0.8 | 6 |
| 279 | Characteristics and care pathways of advanced cancer patients in a palliative-supportive care unit and an oncological ward. <i>Supportive Care in Cancer</i> , 2018, 26, 1961-1966. | 1.0 | 6 |
| 280 | An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. <i>BMC Cancer</i> , 2018, 18, 932. | 1.1 | 6 |
| 281 | Electrochemotherapy as Promising Treatment Option in Rare Recurrent Cutaneous Neoplasm of the Scalp: Case Report of an Elderly Patient. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-5. | 0.2 | 6 |
| 282 | Insulin Resistance as a Risk Factor for Cutaneous Melanoma. A Case Control Study and Risk-Assessment Nomograms. <i>Frontiers in Endocrinology</i> , 2019, 10, 757. | 1.5 | 6 |
| 283 | 'Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation' by Braaten et al: another point of view. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2019-216867. | 0.5 | 6 |
| 284 | Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989985. | 1.4 | 6 |
| 285 | Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. <i>Journal of Personalized Medicine</i> , 2021, 11, 424. | 1.1 | 6 |
| 286 | Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 695136. | 1.3 | 6 |
| 287 | Provision of Palliative Care and Pain Management Services for Oncology Patients. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, S-17-S-27. | 2.3 | 5 |
| 288 | Widespread Renal Polycystosis Induced by Crizotinib. <i>Tumori</i> , 2015, 101, e128-e131. | 0.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 289 | Crizotinib plus radiotherapy in brain oligoprogressive NSCLC ROS1 rearranged and PD-L1 strong. <i>Journal of Thoracic Disease</i> , 2017, 9, E985-E989. | 0.6 | 5 |
| 290 | Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity. <i>Future Oncology</i> , 2020, 16, 129-145. | 1.1 | 5 |
| 291 | Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?. <i>Cancers</i> , 2021, 13, 4061. | 1.7 | 5 |
| 292 | FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?. <i>World Journal of Oncology</i> , 2015, 6, 437-440. | 0.6 | 5 |
| 293 | High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. <i>Journal of Hematology and Oncology</i> , 2022, 15, 9. | 6.9 | 5 |
| 294 | Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10. | 1.4 | 5 |
| 295 | Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome. <i>Current Signal Transduction Therapy</i> , 2012, 7, 265-288. | 0.3 | 4 |
| 296 | A rare case of palatin tonsillar metastasis from small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 709-711. | 1.3 | 4 |
| 297 | Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients. <i>Journal of Cancer</i> , 2016, 7, 516-522. | 1.2 | 4 |
| 298 | Evolving treatments for advanced gastric cancer: appraisal of the survival trend. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 717-729. | 1.1 | 4 |
| 299 | The Incidence of Alcoholism in Patients with Advanced Cancer Receiving Active Treatment in Two Tertiary Care Centers in Italy. <i>Alcohol and Alcoholism</i> , 2019, 54, 47-50. | 0.9 | 4 |
| 300 | Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020, 146, 1917-1929. | 2.3 | 4 |
| 301 | Combination Therapy of High-Dose Rabeprazole Plus Metronomic Capecitabine in Advanced Gastro-Intestinal Cancer: A Randomized Phase II Trial. <i>Cancers</i> , 2020, 12, 3084. | 1.7 | 4 |
| 302 | Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series. <i>Journal of Personalized Medicine</i> , 2020, 10, 291. | 1.1 | 4 |
| 303 | The Challenge of ICLs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?. <i>Frontiers in Immunology</i> , 2021, 12, 704942. | 2.2 | 4 |
| 304 | Patients' Satisfaction with Breakthrough Cancer Pain Therapy: A Secondary Analysis of IOPS-MS Study. <i>Cancer Management and Research</i> , 2022, Volume 14, 1237-1245. | 0.9 | 4 |
| 305 | Pain evaluation and management: a survey of Italian radiotherapists. <i>Supportive Care in Cancer</i> , 2005, 13, 215-218. | 1.0 | 3 |
| 306 | Natural medicine: a "new frontier" in oncology?. <i>Annals of Oncology</i> , 2005, 16, 339-340. | 0.6 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 307 | Ethics in Oncology: Principles and Responsibilities Declared in the Italian Ragusa Statement. <i>Tumori</i> , 2016, 102, e25-e27. | 0.6 | 3 |
| 308 | Knowledge and Attitudes of Young Italian Medical Oncologists Toward the Approach and Treatment of Pain: No Changes, Despite the Law. <i>Pain Medicine</i> , 2017, 18, 1822-1824. | 0.9 | 3 |
| 309 | BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories. <i>Diagnostics</i> , 2019, 9, 146. | 1.3 | 3 |
| 310 | Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a survey about Italian physicians' practice. <i>Supportive Care in Cancer</i> , 2019, 27, 3531-3535. | 1.0 | 3 |
| 311 | Preliminary results of a counselling programme for fertility preservation in female cancer patients: The experience of the GEMME DORMIENTI network. <i>European Journal of Cancer Care</i> , 2020, 29, e13174. | 0.7 | 3 |
| 312 | Gynecological and reproductive factors and the risk of pancreatic cancer: A case-control study. <i>Pancreatology</i> , 2020, 20, 1149-1154. | 0.5 | 3 |
| 313 | Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer. <i>Cancers</i> , 2020, 12, 2457. | 1.7 | 3 |
| 314 | Adding pertuzumab to adjuvant therapy for high-risk HER2-positive early breast cancer in APHINITY: a GRADE analysis. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 423-430. | 0.6 | 3 |
| 315 | Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinoma. <i>Endocrine</i> , 2020, 68, 230-232. | 1.1 | 3 |
| 316 | A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer. <i>Current Oncology</i> , 2021, 28, 1957-1961. | 0.9 | 3 |
| 317 | Preliminary safety results of an Italian early-access program (EAP) with cabazitaxel plus prednisone (CbzP) in patients with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 253-253. | 0.8 | 3 |
| 318 | PAX3d mRNA over 2.76 copies/ μ L in the bloodstream predicts cutaneous malignant melanoma relapse. <i>Oncotarget</i> , 2017, 8, 85479-85491. | 0.8 | 3 |
| 319 | Prediction of Recurrence by Machine Learning in Salivary Gland Cancer Patients After Adjuvant (Chemo)Radiotherapy. <i>In Vivo</i> , 2021, 35, 3355-3360. | 0.6 | 3 |
| 320 | Multi-omic approach identifies a transcriptional network coupling innate immune response to proliferation in the blood of COVID-19 cancer patients. <i>Cell Death and Disease</i> , 2021, 12, 1019. | 2.7 | 3 |
| 321 | The Potential Role of Genomic Signature in Stage II Relapsed Colorectal Cancer (CRC) Patients: A Mono-Institutional Study. <i>Cancer Management and Research</i> , 2022, Volume 14, 1353-1369. | 0.9 | 3 |
| 322 | Palliative Care in Advanced Cancer Patients: Waiting for Godot. <i>Oncologist</i> , 2012, 17, e8-9; author reply e12. | 1.9 | 2 |
| 323 | The Pan European Emesis Registry (PEER): a critical appraisal of the Italian experience. <i>Journal of Chemotherapy</i> , 2013, 25, 309-317. | 0.7 | 2 |
| 324 | Multidisciplinary approach to fetal adenocarcinoma of the lung: A case report. <i>Thoracic Cancer</i> , 2014, 5, 97-100. | 0.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 325 | Supportive care services in hemato-oncology centers: a national survey. <i>Supportive Care in Cancer</i> , 2016, 24, 4407-4411. | 1.0 | 2 |
| 326 | Risk Management of Onco-Hematological Drugs: How and how Fast can we Improve?. <i>Tumori</i> , 2016, 102, S15-S29. | 0.6 | 2 |
| 327 | Complete Tumor Response with Afatinib 20Âmg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. <i>Clinical Drug Investigation</i> , 2017, 37, 581-585. | 1.1 | 2 |
| 328 | Four lines of anaplastic lymphoma kinase inhibitors and brain radiotherapy in a long-surviving non-small-cell lung cancer anaplastic lymphoma kinase-positive patient with leptomeningeal carcinomatosis. <i>Anti-Cancer Drugs</i> , 2019, 30, 201-204. | 0.7 | 2 |
| 329 | Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. <i>Outline of the ARIAS Trial. Cancers</i> , 2020, 12, 849. | 1.7 | 2 |
| 330 | Oxycodone/Acetaminophen: The Tailoring Combination Treatment for Specific Clinical Profile of Opioid Well-Responsive Cancer Pain. <i>Cancer Management and Research</i> , 2021, Volume 13, 1747-1756. | 0.9 | 2 |
| 331 | A Longitudinal Study of Breakthrough Cancer Pain: An Extension of IOPS-MS Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2273. | 1.0 | 2 |
| 332 | An Example of Personalized Treatment in HR+ HER2+ Long Survivor Breast Cancer Patient (Case) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 4 | 0.9 | 2 |
| 333 | Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. <i>Translational Lung Cancer Research</i> , 2021, 10, 2955-2969. | 1.3 | 2 |
| 334 | Vitiligo-like leukodermaÂas an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1. | 1.2 | 2 |
| 335 | Effect of nutritional support with highly purified, whey proteins for malnutrition and sarcopenia in patients affected with stage II-III colorectal or breast cancer: A blind, placebo controlled, randomized clinical trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS10129-TPS10129. | 0.8 | 2 |
| 336 | A 17-Gene Expression Signature for Early Identification of Poor Prognosis in Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 178. | 1.7 | 2 |
| 337 | Molecular landscape and actionable alterations in a genomic-guided cancer clinical trial: First analysis of the ROME trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3087-3087. | 0.8 | 2 |
| 338 | Inappropriate Doses of Chemotherapy in Italian Breast Cancer Patients Enrolled in Clinical Trials. <i>Tumori</i> , 2007, 93, 540-543. | 0.6 | 1 |
| 339 | Re. â€œAwareness and consideration of malnutrition among oncologists: Insights from an exploratory surveyâ€. <i>Nutrition</i> , 2017, 39-40, 96-97. | 1.1 | 1 |
| 340 | 4th ESPT Conference: pharmacogenomics and personalized medicineÂâ€ research progress and clinical implementation. <i>Pharmacogenomics</i> , 2019, 20, 1063-1069. | 0.6 | 1 |
| 341 | Response to: Comment on â€œImpact of tumor site on the prognosis of small bowel adenocarcinomaâ€. <i>Tumori</i> , 2019, 105, 532-532. | 0.6 | 1 |
| 342 | Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis. <i>Journal of Translational Medicine</i> , 2020, 18, 446. | 1.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 343 | Phase 2 of coronavirus disease (COVID-19) and head and neck cancer: An action plan. <i>Oral Diseases</i> , 2022, 28, 970-972. | 1.5 | 1 |
| 344 | Risk of coronavirus disease 2019 in patients treated for cancer: An immune response-based hypothesis. <i>European Journal of Cancer</i> , 2020, 134, 6-8. | 1.3 | 1 |
| 345 | Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era. <i>Journal of Translational Medicine</i> , 2021, 19, 303. | 1.8 | 1 |
| 346 | The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1055-1055. | 0.8 | 1 |
| 347 | Differential clinical outcome of metastatic colorectal cancer (MCRC) patients (pts) treated with first line Flr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy according to KRAS, NRAS and BRAF genotype detected by massive parallel sequencing.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15041-e15041. | 0.8 | 1 |
| 348 | The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature. <i>Frontiers in Oncology</i> , 2022, 12, 797157. | 1.3 | 1 |
| 349 | Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. <i>Tumori</i> , 2014, 100, e309-13. | 0.6 | 1 |
| 350 | Suppressive immune profile in combined positive score positive head and neck cancer patients treated with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18014-e18014. | 0.8 | 1 |
| 351 | Timed-Flat Infusion of 5-Fluorouracil Associated with Docetaxel as First-Line Treatment of Patients with Metastatic Breast Cancer. <i>Breast Journal</i> , 2008, 14, 116-117. | 0.4 | 0 |
| 352 | Clinical and psychometric validation of the BreSAS questionnaire module for symptom assessment among breast cancer survivors. <i>Supportive Care in Cancer</i> , 2020, 28, 1051-1058. | 1.0 | 0 |
| 353 | Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. <i>Breast Care</i> , 2020, 15, 30-37. | 0.8 | 0 |
| 354 | Treatment and outcome(s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, e15568-e15568. | 0.8 | 0 |
| 355 | A proposed new model for prognostic stratification of poor-risk patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15588-e15588. | 0.8 | 0 |
| 356 | Commentary on "A Case of Paratesticular Leiomyosarcoma Successfully Treated with Orchiectomy and Chemotherapy". <i>Cancer Research and Treatment</i> , 2016, 48, 422-424. | 1.3 | 0 |
| 357 | Prognostic factors associated with survival and recurrence in resectable gastroesophageal adenocarcinoma: retrospective analysis of 497 patients operated at two Italian centers.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15588-e15588. | 0.8 | 0 |
| 358 | Systemic effect of radiotherapy (RT) followed by programmed death 1 (PD-1) inhibitors in non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 177-177. | 0.8 | 0 |
| 359 | Next-generation expression analysis (NanoString) to develop prognostic and predictive gene signatures for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 700-700. | 0.8 | 0 |
| 360 | Anatomic site of metastases can influence response to nivolumab in NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15021-e15021. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 361 | Updated outcomes of previously irradiated non-small-cell lung cancer (NSCLC) patients (pts) receiving programmed death 1 (PD-1) inhibitors.. Journal of Clinical Oncology, 2018, 36, e15158-e15158. | 0.8 | 0 |
| 362 | Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in <i>RAS</i> wild-type metastatic colorectal cancer patients: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.. Journal of Clinical Oncology, 2018, 36, e15517-e15517. | 0.8 | 0 |
| 363 | Nab-paclitaxel (Nab-P) in patients (pts) with HER2-ve advanced breast cancer (ABC): A focus on the elderlyâ€” Preliminary results of the GIM-13 AMBRA study.. Journal of Clinical Oncology, 2018, 36, e13078-e13078. | 0.8 | 0 |
| 364 | The microbiota impact: bacteria shaping immunity, disease and response to therapy. Translational Cancer Research, 2018, 7, S616-S619. | 0.4 | 0 |
| 365 | Is it possible to teach pain therapy playing basketball?. Annals of Palliative Medicine, 2016, 5, 71-3. | 0.5 | 0 |
| 366 | Immunotherapy and chemo-immunotherapy for nonâ€”small cell lung cancer with novel actionable oncogenic driver alterations.. Journal of Clinical Oncology, 2022, 40, 9057-9057. | 0.8 | 0 |
| 367 | Network analysis to determine association between immuno-related toxicities and immune soluble profile in patients treated with antiâ€”PD-1.. Journal of Clinical Oncology, 2022, 40, 2553-2553. | 0.8 | 0 |